Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Clicks: 242
ID: 5762
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1,336 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
Reference Key
lindsey2019profileinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lindsey M Childs-Kean;Natalie A Brumwell;Emma F Lodl and
Journal Infection and drug resistance
Year 2019
DOI
10.2147/IDR.S171338
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.